Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.

Chicago, IL—Based on the results of a phase 3 study, patients with advanced lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations experience extended progression-free survival (PFS) when treated with the investigational ErbB receptor family blocker afatinib as single-agent therapy compared with standard chemotherapy.

Chicago, IL—Data presented at ASCO 2013 from the phase 3 clinical trial, known as LUX-Lung 6, show that Asian patients with epidermal growth factor receptor (EGFR) or ErbB1 mutation–positive advanced non–small-cell lung cancer (NSCLC) who were treated with first-line afatinib (Gilo­trif) had a doubling in progression-free survival (PFS) compared with treatment with standard chemotherapy with gemcitabine and cisplatin.

New data from an interim analysis of the head-to-head, open-­label, phase 3, Japanese study J-ALEX show that alectinib (Alecensa) significantly improved progression-free survival (PFS) compared with crizotinib (Xalkori) in the frontline setting, said Hiroshi Nokihara, MD, PhD, of the National Cancer Center Hospital, Tokyo, Japan.

Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Dr. Edward Garon believes it's important to recognize that agents without efficacy are not beneficial to the patient despite low toxicity.
Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice.
Dr. Edward Garon provides an overview of the most common presenting clinical features in adults with non-small cell lung cancer (NSCLC).

Crizotinib, an inhibitor of the anaplastic lymphoma kinase (ALK) gene, has shown significant response rates in patients with advanced non–small-cell lung cancer (NSCLC) and the ALK rearrangement. A new study compared the response rates of standard chemotherapy with crizotinib in patients with ALK-positive advanced NSCLC (Shaw AT, et al. N Engl J Med. 2013;368:2385-2394).

Chicago, IL—Advances in the treatment of non–small-cell lung cancer (NSCLC) to date have focused on mutations in the epidermal growth factor receptor (EGFR) gene, sensitivity to various oncologic agents, the effects of chemotherapy versus single drug on quality of life, and oncologic drug development, said Paul A. Bunn, Jr, MD, James Dudley Chair in Cancer Research, University of Colorado Denver, at ASCO 2013.

Page 1 of 3
Results 1 - 10 of 24
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME